A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Epistemonikos ID: 0446475b084fe01da176a55d6452ecb67bc9979c
First added on: May 07, 2024